Discontinued — last reported Q4 '23
Edwards Lifesciences Debt Securities, Available-for-Sale, Maturity, without Single Maturity Date, Amortized Cost decreased by 21.2% to $45.00M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 40.0%, from $75.00M to $45.00M. This is a positive signal — lower values indicate better performance for this metric.
An increase indicates higher exposure to complex, non-standard debt instruments which may carry higher prepayment or duration risk.
This represents the amortized cost of available-for-sale debt securities that do not have a single, fixed maturity date,...
Standard disclosure for insurance companies managing complex investment portfolios.
other_available_for_sale_securities_debt_maturities_with_06797b| Q2 '21 | Q3 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $253.70M | $353.20M | $503.60M | $471.10M | $491.40M | $345.40M | $306.10M | $258.10M | $163.30M | $123.60M | $98.40M | $75.00M | $65.50M | $57.10M | $45.00M |
| QoQ Change | — | +39.2% | +42.6% | -6.5% | +4.3% | -29.7% | -11.4% | -15.7% | -36.7% | -24.3% | -20.4% | -23.8% | -12.7% | -12.8% | -21.2% |
| YoY Change | — | — | — | +85.7% | +39.1% | -31.4% | -35.0% | -47.5% | -52.7% | -59.6% | -61.9% | -54.1% | -47.0% | -42.0% | -40.0% |